Can-Fite BioPharma Ltd. (CANF), a biotechnology company, on Monday announced the publication of positive results from a pilot study of Piclidenoson in treating canine osteoarthritis in the peer-reviewed journal Frontiers in Veterinary Science, which is available online.
Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals.
In the pilot study, client-owned dogs with spontaneously developed osteoarthritis were administered 500 µg/kg BID of Piclidenoson. According to the trial findings, there was a significant improvement in Liverpool Osteoarthritis in Dogs (LOAD) scores, and pain scores measured by visual assessment scores (VAS). The treated canine subjects also showed a reduction in veterinarian-assessed lameness and pain and demonstrated a favorable safety profile.
A Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs, being conducted by Vetbiolix, has completed enrollment, with topline results expected in the third quarter of 2026.
CANF is currently trading at $3.53, up 3.44%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.